0
Home
News
Directory
E-newsletter
Magazine
Events
Data
AgReport
Subscribe
Bayer launches new fungicide seed treatment Scenic in Chile
Apr. 21, 2017
Bayer CropScience Chile
ChileFollow
ChileReport
- Seed Market by Type (GM Seed, Conventional Seed), Crop Type (Cereals & Grains, Fruits & Vegetables, Oilseeds), Seed Treatment (Treated, Non-treated), Trait (Herbicide-tolerant, Insecticide-resistant), and Region - Global Forecast to 2022
- Top 10 Trends in Agricultural Biologicals Market Industry (Biopesticides, Biostimulants, Biofertilizers, Agricultural Inoculants, Agricultural Microbials, and Biological Seed Treatment) - Global Forecast to 2022
Bayer Chile has presented Scenic—its new cutting-edge product for fungicide seed treatment of cereals.
Following the motto, “Protect your effort with innovation and technology,” the Germany company had invited 300 farmers, advisers, seeders and distributors to the Municipal Theater of Temuco.
Scenic is a new fungicide with systemic action, based on three active ingredients: fluoxastrobin, prothioconazole and tebuconazole. The components allow a wide spectrum control for combating diseases, such as Septoria, Oidios and Rhynchosporium secalis, which affect wheat and other cereals.
The presentation was made by the Crop Science division staff: Pablo Herrera, key account manager, Alvaro Florín, business adviser and Edmundo Klein, director of the Experiment Center of Temuco. The technological evolution of seed treatment was shown, as well as the functionalities and benefits of Scenic in a new and innovative manner through a so-called Token, which allowed interacting in a tablet, enlarging, surrounding and drawing on the images.
According to Bayer, the product is compatible with the insecticide Gaucho ®600 FS (imidacloprid) and Regent®250 FS (fipronil), as well as the seed coaters Poncho®600 FS (clothianidin), Janus®480 FS (clothianidin + beta-cyfluthrin) and the Peridiam Ferti coating.
 |
 |
 |
Click to enlarge the mages.
Source: AgroNews
More from AgroNews
Change
Hot TopicSubscribe
| Subscribe Email: | * | |
| Name: | ||
| Mobile Number: | ||
Comment
0/1200
NEWSLETTER